Drug intelligence / Profile preview

AC607

Development stage: Discontinued
Lead developer: AlloCure
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

AC607 is an allogeneic, bone marrow-derived mesenchymal stem cell (MSC) therapy developed by AlloCure for the prevention and treatment of acute kidney injury (AKI). The therapy was primarily investigated in patients undergoing on-pump cardiac surgery who are at high risk for post-operative renal complications. AC607 functions by leveraging the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs, which are thought to migrate to the site of injury and secrete paracrine factors that promote tissue repair and reduce inflammation. Despite receiving FDA Fast Track designation and showing promise in Phase 1, a Phase 2 multicenter trial (ACT-AKI) was terminated, and development of the candidate appears to have ceased.

Other names: AlloCure MSCsallogeneic mesenchymal stem cells

Beyond the preview

Go deeper on AC607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC607.

Explore the full profile